Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AMED | Common Stock | Options Exercise | $897K | +11.2K | +19.92% | $79.82 | 67.7K | Dec 26, 2023 | Direct | |
transaction | AMED | Common Stock | Tax liability | -$965K | -10.1K | -14.99% | $95.14 | 57.5K | Dec 26, 2023 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AMED | Stock Option (Right to Buy) | Options Exercise | $0 | -11.2K | -33.33% | $0.00 | 22.5K | Dec 26, 2023 | Common Stock | 11.2K | $79.82 | Direct | F1 |
Id | Content |
---|---|
F1 | On April 12, 2023, the reporting person was granted 33,711 Stock Options subject to time-based vesting conditions to vest in equal, 1/3 installments on each of February 20, 2024, 2025 and 2026, subject to continued employment. 11,237 of the Stock Options were accelerated from February 2024 to December 21, 2023 in order to mitigate impacts that could arise under Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended. The Reporting Person has signed a letter agreement providing that the shares of common stock underlying such accelerated Stock Options are subject to certain forfeiture conditions. The remaining 22,474 Stock Options are subject to the original vesting terms (half of which will vest on February 20, 2025 and the remaining half will vest on February 20, 2026). |